Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

3Total

P 1 (1)

P 3 (2)

Trial Status

Completed4

Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (5)

Showing 5 of 5 trials

NCT07012356Completed

Does Hr-HPV Status Influence the 2011 IFCPC Nomenclature and Swede Score's Capacity to Diagnose Precancerous Lesions?

NCT03721978Phase 3Completed

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT06208319Unknown

Development and Evaluation of an Artificial Intelligence Tool for Colposcopy Assistance

NCT03185013Phase 3Completed

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03239223Phase 1CompletedPrimary

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

Showing all 5 trials

HSIL